To include your compound in the COVID-19 Resource Center, submit it here.

AMR-001: Additional Phase II data

Additional data from the double-blind, U.S. Phase II PreSERVE AMI trial in 161 patients diagnosed with an ST-segment elevation myocardial infarction (STEMI) showed that intracoronary AMR-001 given 5-11 days post-stent placement led to a mean reduction

Read the full 366 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE